Showing 1 posts of 1 posts found.
Novartis has submitted two new lung treatments for FDA approval after ‘robust’ Phase III trial results. If approved, QVA149 and …
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
Brenntag and dsm-firmenich expand biopharma vitamin partnership
CeramTec expands German production capacity for orthopaedic ceramics
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership